新型冠状病毒肺炎患者心血管损伤机制研究进展  

Mechanism of Cardiovascular Damage in Patients with Corona Virus Disease 2019

作　　者：陈捷 王宏宇[1,2,3] CHEN Jie;WANG Hongyu(Department of Vascular Medicine,Peking University Shougang Hospital,Beijing 100144,China;Vascular Health Research Center of Peking University Health Science Center,Beijing 100144,China;Key Laboratory of Molecular Cardiovascular Sciences(Peking University),Ministry of Education,Beijing 100144,China)

机构地区：[1]北京大学首钢医院血管医学中心,北京100144 [2]北京大学医学部血管健康研究中心,北京100144 [3]北京大学分子心血管学教育部重点实验室,北京100144

出　　处：《心血管病学进展》2021年第5期401-403,共3页Advances in Cardiovascular Diseases

基　　金：教育部科技发展中心产学研创新基金“智融兴教”基金(2018A02004);国家重点研发计划(2017YFC0113005);国家重点研发计划(2017YFC0113003);2019年度临床重点项目(2019-Yuan-LC-01);2020年首都卫生发展科研专项(首发2020-2-6042)。

摘　　要：2019新型冠状病毒(2019-nCoV)是引起新型冠状病毒肺炎(COVID-19)大爆发的病毒,其通过病毒表面棘突蛋白与血管紧张素转换酶2受体结合而感染细胞,导致内皮细胞损伤,引起“炎症因子风暴”,造成凝血功能障碍,甚至导致死亡。随着对COVID-19发病机制研究的深入,COVID-19逐渐被视为一种血管性疾病,现主要就COVID-19患者心血管损伤的可能机制做一综述。2019-nCoV is a virus that causes the outbreak of COVID-19.It infects cells through the combination of the surface spike protein and the angiotensin-converting enzyme 2 receptor,resulting in endothelial cell injury,causing“inflammatory factor storm”,resulting in coagulation dysfunction and even death.With the development of the research on the pathogenesis of COVID-19,COVID-19 has gradually been regarded as a vascular disease.This paper mainly reviews the possible mechanism of cardiovascular injury in patients with COVID-19.

关 键 词：2019-nCoV COVID-19 血管紧张素转换酶2 血管病变 

分 类 号：R563.1[医药卫生—呼吸系统]